立体定向体部放疗治疗转移性去势抵抗性前列腺癌的现状
本系统综述检索2024年3月Pubmed文献共108篇、纳入19篇,总结立体定向体部放疗(SBRT)在去势抵抗性前列腺癌(CRPC)中的证据。文献以回顾性系列为主;一项随机II期试验中,SBRT联合雄激素受体通路抑制剂显著延长无进展生存期(风险比0.35,p<0.001)。结论认为SBRT可使寡转移CRPC获得长期生化缓解和PFS,但证据水平仍很低,首选纳入前瞻性试验。
要点
- 一项随机II期试验显示SBRT联合雄激素受体通路抑制剂显著延长无进展生存期(风险比0.35,p<0.001)。
- 继续ADT的患者中,SBRT后生化无进展生存期为9.5个月至17.9个月,至下次系统治疗免于生存达2年。
- 各研究报告的3级毒性均低于5%,SBRT耐受性良好。
核心结论
- 在寡转移CRPC人群中,SBRT可实现长期生化缓解和无进展生存。
- 在寡进展情况下,SBRT可整合用于延长系统治疗的持续时间和疗效。
- 证据水平仍很低,对该人群首选纳入前瞻性试验。
研究设计与样本
- 系统综述,检索2024年3月Pubmed,关键词为「SBRT」和「CRPC」以及「立体定向消融放疗(SABR)」和「CRPC」,共检索108篇文章,纳入19篇。
- 纳入文献以回顾性系列为主。
主要发现
- 在异时性寡进展男性中,一项随机II期试验显示SBRT联合雄激素受体通路抑制剂显著增加无进展生存期(包括生化无进展生存期),风险比0.35,p<0.001。
- 在继续ADT的患者中,生化无进展生存期为9.5个月至17.9个月,至下次系统治疗免于生存达2年。
- 在诱导性寡进展男性中,SBRT使至下次系统治疗免于生存达3年。
- SBRT耐受性良好,各研究报告的3级毒性低于5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据水平仍很低。
- 对该人群首选纳入前瞻性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The onset of castration-resistance is associated with dismal outcomes in patients with prostate cancer (PCa). Metastasis directed therapy has been investigated in multiple disease settings and may improve outcomes in selected patients. Our systematic review aims to summarize evidence with stereotactic body radiotherapy (SBRT) in castration-resistant prostate cancer (CRPC). METHODS: The literature search was performed on March 2024, on Pubmed, using the keywords "SBRT" AND "CRPC", and "stereotactic ablative radiotherapy (SABR)" AND "CRPC". This search retrieved a total of 108 articles, 19 were included. RESULTS: The literature is largely dominated by retrospective series. In men with metachronous oligoprogression, SBRT with androgen receptor pathway inhibitor significantly increased progression-free survival (PFS) including biochemical progression-free survival in a randomized phase II trial (hazard ratio of 0.35, p < 0.001). In patients continuing ADT, the bPFS ranged between 9.5 months to 17.9 months, and next systemic treatment-free survival (NEST-FS) reached up to 2 years. In men with induced oligoprogression, SBRT enabled NEST-FS up to 3 years. SBRT was well tolerated, with less than 5% grade 3 toxicity reported across studies. CONCLUSION: In the population of patients with oligometastatic CRPC, SBRT enables long-term biochemical response and PFS. In the oligoprogressive setting, SBRT could be integrated to prolong the duration and efficacy of systemic therapies. Nevertheless, the level of evidence remains very low and inclusion within prospective trials remain the preferred option for this population of patients.
引用
- Le Guevelou J, Cuccia F, Flippot R, et al. The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 38898265. doi:10.1038/s41391-024-00862-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。